Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients

References

• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975–2014. Bethesda, MD: National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
   Google Scholar
• Pagano L, Mele L, Casorelli I, et al. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 2000;85:1327–1329.
   PubMed Web of Science ®Google Scholar
• Thomas X, Olteanu N, Charrin C, et al. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67:73–83.
   PubMed Web of Science ®Google Scholar
• Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematol J. 2002;3:219–223.
   PubMedGoogle Scholar
• Brandwein JM, Gupta V, Wells RA, et al. Treatment of elderly patients with acute lymphoblastic leukemia-evidence for a benefit of imatinib in BCR-ABL positive patients. Leukemia Res. 2005;29:1381–1386.
   PubMed Web of Science ®Google Scholar
• Shin DY, Kim I, Kim KH, et al. Acute lymphoblastic leukemia in elderly patients: a single institution's experience. Korean J Intern Med. 2011;26:328–339.
   PubMedGoogle Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463–471.
   PubMed Web of Science ®Google Scholar
• Gokbuget N. How I treat older patients with ALL. Blood. 2013;122:1366–1375.
   PubMed Web of Science ®Google Scholar
• Marks DI. The challenges of managing older patients with acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2015; 35:e343–e351.
   Google Scholar
• Kozlowski P, Lennmyr E, Ahlberg L, et al. Age but not Philadelphia positivity impairs outcome in older/elderly patients with Acute Lymphoblastic Leukemia in the Swedish population. Eur J Haematol. 2017;99:141–149.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–1411.
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Venkitachalam R, Mehta P. Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database. Leuk Lymph. 2015;56:2296–2300.
   PubMed Web of Science ®Google Scholar
• Li S, Molony JT, Chia VM, et al. Mortality among elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data. J Clin Oncol. 2016;34(15):7022–7022
   Web of Science ®Google Scholar
• Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017;15:266–274.
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US food and drug administration. J Clin Oncol. 2004;22:4626–4631.
   PubMed Web of Science ®Google Scholar
• Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30:2036–2038.
   PubMed Web of Science ®Google Scholar
• Bindu Kanapuru M, Harpreet Singh M, Myers A, et al. Enrollment of older adults in clinical trials evaluating patients with hematologic malignancies – the Food and Drug Administration (FDA) Experience [abstract]. Atlanta (GA): American Society of Hematology; 2017.
   Google Scholar
• Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–1164.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113:2097–2101.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Byun JM, Koh Y, Shin D-Y, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. Haematologica. 2017;102:e187–e190.
   PubMed Web of Science ®Google Scholar
• Saillard C, Etienne A, Charbonnier A, et al. Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. Leuk Lymph. 2014;55:2211–2212.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Beck J, Brueggemann M, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative Acute Lymphoblastic Leukemia (ALL): results of a prospective trial from the german Multicenter Study Group for Adult ALL (GMALL). Blood. 2012;120:1493–1493.
   Web of Science ®Google Scholar
• Rosko AE, Wang H-L, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017;92:42–49.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Kenderian SS, Al-Kali A, Gangat N, et al. Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood Cancer J. 2013;3:e122.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115:206–214.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Dagis A, Palmer J, et al. Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome. Bone Marrow Transplant. 2015;50:746–748.
   PubMed Web of Science ®Google Scholar
• Abdulwahab A, Sykes J, Kamel-Reid S, et al. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012;118:3962–3967.
   PubMed Web of Science ®Google Scholar
• Swaika A, Frank RD, Yang D, et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2018;7:499–507.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant.: J Am Soc Blood Marrow Transplant. 2009;15:1628–1633.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35:394–401.
   PubMed Web of Science ®Google Scholar
• Poch Martell M, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163:458–464.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leukemia Research. 2016;41:12–20.
   PubMed Web of Science ®Google Scholar
• Sancho J-M, Ribera J-M, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78:102–110.
   PubMed Web of Science ®Google Scholar
• Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43:126–133.
   PubMed Web of Science ®Google Scholar
• Burmeister T, Schwartz S, Bartram CR, et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–919.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774–782.
   PubMed Web of Science ®Google Scholar
• Litzow MR. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?. Best Practice Res Clin Haematol. 2016;29:345–350.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–4443.
   PubMed Web of Science ®Google Scholar
• Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116:366–374.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016;122:2178–2185.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19:240–248.
   PubMed Web of Science ®Google Scholar
• Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131:515–524.
   PubMed Web of Science ®Google Scholar